New drug PEP-010 shows promise in early trial for Hard-to-Treat cancers
NCT ID NCT04733027
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 25 times
Summary
This early-phase study tests a new drug called PEP-010, given alone or with chemotherapy (paclitaxel or gemcitabine), in people with metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, and to see if the drug can shrink tumors in pancreatic and ovarian cancers. About 57 participants are enrolled across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CLCC F.Baclesse Caen
Caen, France
-
Gustave Roussy
Villejuif, France
-
Institut Curie
Paris, 75005, France
-
Institut de Cancerologie de l'Ouest- ICO
Saint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.